| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-663 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- |
| filingDate |
1995-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1999-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H11502506-A |
| titleOfInvention |
Bone mass assimilation composition comprising orpadronate |
| abstract |
(57) [Summary]nThe present invention provides a method of maintaining or increasing bone mass assimilation in human or other animal subjects affected by osteoporosis or other bone metabolic disorders characterized by systemic or local bone loss by using a bisphosphonate formulation. provide. Here, the bone mass assimilation composition comprises an effective non-toxic amount of [3- (N, N-dimethyl-amino) -1-hydroxypropylidene] -bisphosphonic acid or olpadronate, or its monosodium salt or pharmaceutical. It contains other salts that are chemically acceptable. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8853187-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004519463-A |
| priorityDate |
1994-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |